Cargando…
Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes
PURPOSE: To assess the safety of biosimilar intravitreal aflibercept (CinnaGen Co., Iran) compared to the reference product (Eylea®; Bayer Schweiz AG, Zurich, Switzerland) in rabbit eyes through functional and histologic studies. METHODS: Forty New Zealand albino rabbits were recruited to the study...
Autores principales: | Lashay, Alireza, Riazi-Esfahani, Hamid, Faghihi, Hooshang, Mirshahi, Ahmad, Khojasteh, Hassan, Khodabande, Alireza, Amoli, Fahimeh Asadi, Ghassemi, Fariba, Bazvand, Fatemeh, Khalili Pour, Elias, Ebrahimiadib, Nazanin, Torkashvand, Ali, Delrish, Elham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7354659/ https://www.ncbi.nlm.nih.gov/pubmed/32714608 http://dx.doi.org/10.1155/2020/2602918 |
Ejemplares similares
-
Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
por: Lashay, Alireza, et al.
Publicado: (2020) -
Intraocular Injection of StivantⓇ (A Biosimilar to Bevacizumab): A Case Series
por: Mirshahi, Ahmad, et al.
Publicado: (2021) -
Choroidal features in flat irregular pigment epithelial detachment associated with Chronic central serous chorioretinopathy: Avascular versus vascularized
por: Faghihi, Hooshang, et al.
Publicado: (2021) -
Flat irregular pigment epithelial detachment over time and outcome of different treatment regimens
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2022) -
Hypertension and Ischemic Stroke After Aflibercept for Retinopathy of Prematurity
por: Bazvand, Fatemeh, et al.
Publicado: (2020)